TRPV2 is a Novel Biomarker and Therapeutic Target in Triple Negative Breast Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Oct 17

PMID 30323891

Citations 39

Authors

Mohamad Elbaz

Dinesh Ahirwar

Zhang Xiaoli

Xinyu Zhou

Maryam Lustberg

Mohd W Nasser

Konstantin Shilo

Ramesh K Ganju

Affiliations

Soon will be listed here.

Abstract

Transient receptor potential vanilloid type-2 (TRPV2) is an ion channel that is triggered by agonists like cannabidiol (CBD). Triple negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Chemotherapy is still the first line for the treatment of TNBC patients; however, TNBC usually gains rapid resistance and unresponsiveness to chemotherapeutic drugs. In this study, we found that TRPV2 protein is highly up-regulated in TNBC tissues compared to normal breast tissues. We also observed that TNBC and estrogen receptor alpha negative (ERβ-) patients with higher TRPV2 expression have significantly higher recurrence free survival compared to patients with lower TRPV2 expression especially those who were treated with chemotherapy. In addition, we showed that TRPV2 overexpression or activation by CBD significantly increased doxorubicin (DOX) uptake and apoptosis in TNBC cells. The induction of DOX uptake was abrogated by TRPV2 blocking or downregulation. mouse model studies showed that the TNBC tumors derived from CBD+DOX treated mice have significantly reduced weight and increased apoptosis compared to those treated with CBD or DOX alone. Overall, our studies for the first time revealed that TRPV2 might be a good prognostic marker for TNBC and ERβ- breast cancer patient especially for those who are treated with chemotherapy. In addition, TRPV2 activation could be a novel therapeutic strategy to enhance the uptake and efficacy of chemotherapy in TNBC patients.

Citing Articles

TRP channels and breast cancer: the role of TRPs in the pathophysiological development.

Zhang Y, Yi Y, Shu Y, Ru X, He S Front Mol Biosci. 2025; 12:1528663.

PMID: 40078961 PMC: 11896876. DOI: 10.3389/fmolb.2025.1528663.

Brief Magnetic Field Exposure Stimulates Doxorubicin Uptake into Breast Cancer Cells in Association with TRPC1 Expression: A Precision Oncology Methodology to Enhance Chemotherapeutic Outcome.

Sukumar V, Tai Y, Chan C, Iversen J, Wu K, Fong C Cancers (Basel). 2024; 16(22).

PMID: 39594815 PMC: 11592624. DOI: 10.3390/cancers16223860.

Improved Therapeutic Efficacy of Doxorubicin Chemotherapy With Cannabidiol in 4T1 Mice Breast Cancer Model.

Tabatabaei K, Moazzezi S, Emamgholizadeh M, Vaez H, Baradaran B, Shokouhi B Cancer Med. 2024; 13(21):e70395.

PMID: 39503169 PMC: 11538943. DOI: 10.1002/cam4.70395.

The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine.

Skorzewska M, Geca K Curr Oncol Rep. 2024; 26(11):1334-1348.

PMID: 39110350 PMC: 11579082. DOI: 10.1007/s11912-024-01589-4.

Targeting Nrf2 Signaling Pathway in Cancer Prevention and Treatment: The Role of Cannabis Compounds.

Rybarczyk A, Majchrzak-Celinska A, Krajka-Kuzniak V Antioxidants (Basel). 2023; 12(12).

PMID: 38136172 PMC: 10740807. DOI: 10.3390/antiox12122052.

References

Gogebakan B, Bayraktar R, Suner A, Balakan O, Ulasli M, Izmirli M . Do fasudil and Y-27632 affect the level of transient receptor potential (TRP) gene expressions in breast cancer cell lines?. Tumour Biol. 2014; 35(8):8033-41. DOI: 10.1007/s13277-014-1752-0. View

Yamada T, Ueda T, Shibata Y, Ikegami Y, Saito M, Ishida Y . TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer. Urology. 2010; 76(2):509.e1-7. DOI: 10.1016/j.urology.2010.03.029. View

Dhennin-Duthille I, Gautier M, Faouzi M, Guilbert A, Brevet M, Vaudry D . High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: correlation with pathological parameters. Cell Physiol Biochem. 2011; 28(5):813-22. DOI: 10.1159/000335795. View

Gkika D, Prevarskaya N . TRP channels in prostate cancer: the good, the bad and the ugly?. Asian J Androl. 2011; 13(5):673-6. PMC: 3739589. DOI: 10.1038/aja.2011.18. View

Liu G, Xie C, Sun F, Xu X, Yang Y, Zhang T . Clinical significance of transient receptor potential vanilloid 2 expression in human hepatocellular carcinoma. Cancer Genet Cytogenet. 2010; 197(1):54-9. DOI: 10.1016/j.cancergencyto.2009.08.007. View

Monet M, Lehenkyi V, Gackiere F, Firlej V, Vandenberghe M, Roudbaraki M . Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. Cancer Res. 2010; 70(3):1225-35. DOI: 10.1158/0008-5472.CAN-09-2205. View

Qin N, Neeper M, Liu Y, Hutchinson T, Lubin M, Flores C . TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci. 2008; 28(24):6231-8. PMC: 6670541. DOI: 10.1523/JNEUROSCI.0504-08.2008. View

Bayraktar S, Gluck S . Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2013; 138(1):21-35. DOI: 10.1007/s10549-013-2421-5. View

Mihara H, Boudaka A, Shibasaki K, Yamanaka A, Sugiyama T, Tominaga M . Involvement of TRPV2 activation in intestinal movement through nitric oxide production in mice. J Neurosci. 2010; 30(49):16536-44. PMC: 6634895. DOI: 10.1523/JNEUROSCI.4426-10.2010. View

10.

Liedtke C, Mazouni C, Hess K, Andre F, Tordai A, Mejia J . Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81. DOI: 10.1200/JCO.2007.14.4147. View

11.

Nabissi M, Morelli M, Amantini C, Farfariello V, Ricci-Vitiani L, Caprodossi S . TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. Carcinogenesis. 2010; 31(5):794-803. DOI: 10.1093/carcin/bgq019. View

12.

Karasawa T, Wang Q, Fu Y, Cohen D, Steyger P . TRPV4 enhances the cellular uptake of aminoglycoside antibiotics. J Cell Sci. 2008; 121(Pt 17):2871-9. PMC: 2736053. DOI: 10.1242/jcs.023705. View

13.

Elbaz M, Nasser M, Ravi J, Wani N, Ahirwar D, Zhao H . Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer. Mol Oncol. 2015; 9(4):906-19. PMC: 4387115. DOI: 10.1016/j.molonc.2014.12.010. View

14.

Pogoda K, Niwinska A, Murawska M, Pienkowski T . Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013; 30(1):388. PMC: 3586394. DOI: 10.1007/s12032-012-0388-4. View

15.

Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G . Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 2006; 13(7):1238-41. DOI: 10.1038/sj.cdd.4401872. View

16.

Nasser M, Qamri Z, Deol Y, Smith D, Shilo K, Zou X . Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One. 2011; 6(9):e23901. PMC: 3168464. DOI: 10.1371/journal.pone.0023901. View

17.

McAllister S, Christian R, Horowitz M, Garcia A, Desprez P . Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther. 2007; 6(11):2921-7. DOI: 10.1158/1535-7163.MCT-07-0371. View

18.

Majeed Y, Amer M, Agarwal A, McKeown L, Porter K, ORegan D . Stereo-selective inhibition of transient receptor potential TRPC5 cation channels by neuroactive steroids. Br J Pharmacol. 2010; 162(7):1509-20. PMC: 3057289. DOI: 10.1111/j.1476-5381.2010.01136.x. View

19.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

20.

Hudis C, Gianni L . Triple-negative breast cancer: an unmet medical need. Oncologist. 2011; 16 Suppl 1:1-11. DOI: 10.1634/theoncologist.2011-S1-01. View